Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas 2020-06-04 00:00
Novavax Selects AGC Biologics to Manufacture Matrix-M™ Adjuvant for Novel COVID-19 Vaccine 2020-06-03 19:00
New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis 2020-06-03 14:30
Eleva's Drug Candidate to Be Examined for Use in COVID-19 Treatment 2020-06-03 10:00
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study 2020-06-03 07:30
Firmenich Appoints Boet Brinkgreve as President Ingredients 2020-06-03 00:14
Firmenich Appoints Boet Brinkgreve as President Ingredients 2020-06-02 23:41
Tigermed Lauded by Frost & Sullivan for Its Rapid, Large-Scale Clinical Developmental Services 2020-06-02 22:00
DERMALOG Fever Check at Clever Fit Gym 2020-06-02 21:46
Ajinomoto Bio-Pharma Services Completes Acquisition of Granules OmniChem Joint Venture in India 2020-06-02 20:04
Cellenkos(R) Inc. Announces FDA Clearance to Initiate Phase 1 Double- Blinded, Randomized, Placebo-Controlled Trial of Cryopreserved Cord Blood-Derived T-Regulatory Cells (CK0802) for Treatment of COVID-19 Associated Acute Respiratory Distress Syndrome 2020-06-02 18:00
Innovent Announced the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study 2020-06-02 07:30
AGC Biologics Acquires Commercial Facility, Expanding Global Service Offerings 2020-06-02 06:00
Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal 2020-06-01 08:45
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type) 2020-06-01 07:30
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma 2020-06-01 07:30
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma 2020-06-01 07:30
Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma 2020-06-01 07:30
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type) 2020-06-01 07:30
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma 2020-06-01 07:30
1 301 302 303 304 305 463